Re-evaluation of the Blood-Brain Barrier in the Presence of Alzheimer's Disease Pathology.
Blood-brain barrier disruption is believed to occur in Alzheimer's disease, which could influence the bioavailability of drugs within the brain. However, in this issue of Neuron, Bien-Ly et al. (2015) report no evidence of widespread blood-brain barrier dysfunction.
Department of Neurology, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA; The Knight Alzheimer's Disease Research Center, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA.
Jason D
JD
Ulrich
Department of Neurology, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA; The Knight Alzheimer's Disease Research Center, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA.
Tien-Phat
TP
Huynh
Department of Neurology, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA; Hope Center for Neurological Disorders, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA; The Knight Alzheimer's Disease Research Center, Washington University, 660 South Euclid Avenue, Box 8111, St. Louis, MO 63110, USA. Electronic address: holtzman@neuro.wustl.edu.
David M
DM
Holtzman
D000544:Alzheimer Disease / Q000378:metabolism*; D000818:Animals; D000906:Antibodies / Q000378:metabolism* / Q000627:therapeutic use*; D001812:Blood-Brain Barrier / Q000378:metabolism*; D004195:Disease Models, Animal; D005260:Female; D006801:Humans; D008297:Male
D000906:Antibodies